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Community-acquired respiratory tract infections (RTIs)
account for a substantial proportion of outpatient antimicro-
bial drug prescriptions worldwide. Concern over the emer-
gence of multidrug resistance in pneumococci has largely
been focused on penicillin-resistant Streptococcus pneu-
moniae. Macrolide antimicrobial drugs have been widely
used to empirically treat community-acquired RTIs because
of their efficacy in treating both common and atypical respi-
ratory pathogens, including S. pneumoniae. However,
increased macrolide use has been associated with a glob-
al increase in pneumococcal resistance, which is leading to
concern over the continued clinical efficacy of the
macrolides to treat community-acquired RTIs. We provide
an overview of macrolide-resistant S. pneumoniae and
assess the impact of this resistance on the empiric treat-
ment of community-acquired RTIs.
C
ommunity-acquired respiratory tract infections
(RTIs), including acute bacterial sinusitis, acute otitis
media, acute exacerbations of chronic bronchitis, and com-
munity-acquired pneumonia, are among the most frequent
infections treated by physicians and represent a major
international health problem (1). Community-acquired
pneumonia is one of the leading causes of hospitalization
in the United States and the most common cause of death
in patients with infectious diseases (2), while acute otitis
media is the most frequent illness for which antimicrobial
drugs are prescribed for children in the industrialized
world.  Streptococcus pneumoniae is the most common
microbial pathogen identified in community acquired
RTIs, and pneumococcal infections are among the leading
causes of illness and death worldwide (3), particularly
among children, the elderly, and persons with coexisting
medical conditions.
In the past, β-lactam antimicrobial drugs (e.g., peni-
cillin) were widely used to empirically treat community-
acquired RTIs. Pneumococcal resistance to penicillin was
first observed in the 1960s; since then, the emergence and
spread of penicillin-resistant S. pneumoniae strains have
been observed and tracked worldwide. With the β-lactams
in widespread use, increasing levels of penicillin-resistant
S. pneumoniae were thought to be of greater potential clin-
ical importance than the emergence of macrolide-resistant
S. pneumoniae strains. However, a number of studies and
analyses of patients with pneumococcal pneumonia (4)
have shown no association between penicillin resistance
and patient death, although some studies have indicated
that penicillin-resistant S. pneumoniae infection may be
associated with an increased risk for suppurative compli-
cations, longer hospital stays, and higher treatment costs
(5). 
The growing concerns about the emergence and spread
of drug-resistant pathogens (including penicillin-resistant
S. pneumoniae) and an increased awareness of infection
with atypical pathogens (e.g., Chlamydia pneumoniae,
Mycoplasma pneumoniae, and Legionella pneumophila),
led to the publication of community-acquired pneumonia
treatment guidelines by the American Thoracic Society in
1993 (6). These guidelines included a recommendation
that macrolide drugs be used as first-line empiric therapy
for outpatients with community-acquired pneumonia. The
macrolides have since been used extensively to treat com-
munity-acquired RTIs worldwide. However, increasing
macrolide use has also been associated with an increase in
pneumococcal resistance to these agents, and macrolide-
resistant S. pneumoniae are now more common than peni-
cillin-resistant S. pneumoniae in many parts of the world
(7). We provide an overview of pneumococcal resistance
to macrolides and assess the impact of macrolide-resistant
S. pneumoniae on the empiric treatment of community-
acquired RTIs. 
Macrolide Resistance
Mechanisms of Resistance
Macrolides are microbiostatic agents that reversibly
bind to the 23S ribosomal RNAin the 50S subunit of ribo-
somes and block protein synthesis (8). Two main
macrolide resistance mechanisms have been identified in
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target-site modification (8). Energy-dependent efflux of
macrolides from target cells by a cell membrane trans-
porter has been associated with the presence of mef genes.
Recent work by Iannelli et al. (9) has implicated a second
gene, mat(A), that encoded 2 ATP-binding domains, as a
component of mef-mediated macrolide resistance in pneu-
mococci. Irrespective of the identity of the gene responsi-
ble for macrolide efflux, mef(A)-positive S. pneumoniae
strains displaying this macrolide efflux phenotype (termed
the M phenotype) are resistant to 14- and 15-membered
ring macrolides (but not lincosamides or streptogramins)
and generally display a low level of in vitro resistance to
these antimicrobial agents. However, data from surveil-
lance studies suggest that erythromycin MICs for mef(A)-
positive isolates may be increasing. MICs were 1–16
µg/mL for mef(A)-positive S. pneumoniae isolates collect-
ed from 1994 to 1995 (10), while results from a more
recent study demonstrated an erythromycin MIC of 1 to
>256 µg/mL (11). 
The second major mechanism of macrolide resistance
in streptococci, target-site modification, is predominantly
encoded by the erm(B) gene, resulting in methylation of an
adenine residue on the 23S rRNA by a methylase enzyme.
This methylation blocks the binding of macrolide-lin-
cosamide-streptogramin B antimicrobial drugs. Strains
with the macrolide-lincosamide-streptogramin B pheno-
type generally show higher levels of in vitro resistance to
macrolides compared to strains with the M phenotype (10).
Other target-site modifications occur rarely in clinical
isolates of S. pneumoniae. These modifications include
mutations that involve domain V of the 23S rRNA and
genes encoding riboproteins L4 and L22 (12). Such muta-
tions can confer resistance to macrolide-lincosamide-
streptogramin B antimicrobial drugs and are associated
with variable levels of in vitro resistance. Although the
global prevalence of pneumococcal strains with macrolide
resistance conferred by ribosomal gene mutations remains
low (<2%), a study of macrolide resistance mechanisms
among S. pneumoniae isolated in Canada from 1997 to
2003 indicated that the rate of resistance due to mecha-
nisms other than efflux or ribosomal methylation increased
from 1% in 1997 to 10% in 2003 (13). 
Macrolide Resistance Trends
A number of industry-sponsored global surveillance
studies, such as the Alexander Project (GlaxoSmithKline)
and PROTEKT (Prospective Resistant Organism Tracking
and Epidemiology for the Ketolide Telithromycin) (sanofi-
aventis), have been designed to define and monitor the
prevalence and distribution of antimicrobial resistance
among respiratory pathogens, detect new patterns of resist-
ance, provide early warning of emerging resistance, and
evaluate the effects of interventions aimed at reducing
antimicrobial resistance. Results from the Alexander
Project indicate that in 1996 and 1997 the global rate of
pneumococcal macrolide resistance was16.5%–21.9%
(14); by 1998–2000, the resistance rate had increased to
24.6% (15). Data reported after completion of the first year
of the PROTEKT study (1999–2000 respiratory season)
confirmed this high global incidence (31.0%) of pneumo-
coccal macrolide resistance (7), with similar overall levels
of resistance among isolates collected as part of the PRO-
TEKT US study (31.0% in 2000–2001 and 27.9% in
2001–2002) (16,17). The slight reduction in macrolide
resistance among pneumococcal isolates collected as part
of the PROTEKT US study from 2001 to 2002 may be a
consequence of the February 2000 introduction of the 7-
valent pneumococcal conjugate vaccine (18). 
However, both macrolide resistance rates and resistance
mechanisms may vary considerably depending on loca-
tion. Macrolide resistance rates for isolates collected dur-
ing the PROTEKT US study from 2001 to 2002 vary
according to region; at a state level, the highest prevalence
of pneumococcal macrolide resistance was recorded in
Louisiana (48.2%) and the lowest in Vermont (15.2%)
(11). Similarly, while mef(A) was the most prevalent pneu-
mococcal macrolide resistance genotype identified in the
United States overall (68.7% of genotyped isolates), the
relative prevalence varied by state and ranged from 40% in
Delaware to 85% in Georgia (11). While erm(B) was the
second most prevalent genotype overall (16.8%), isolates
possessing both the erm(B) and mef(A) genotype (12.2%)
were more prevalent in 11 states than those harboring
erm(B) alone. A recent analysis of PROTEKT US
2002–2003 data by Farrell et al. (19) indicates an increase
in the prevalence of macrolide-resistant isolates containing
both  erm(B) and mef(A) from 9.7% in 2000–2001 to
16.4% in 2002–2003. Most (99.2%) of these erm(B) +
mef(A)–positive isolates were resistant to >2 classes of
antimicrobial drugs. Analysis of erythromycin MIC data
for all macrolide-resistant isolates collected in 2000–2001
indicated that the MIC90 (MIC at which 90% of isolates
were inhibited) varied according to resistance genotype
(16 µg/mLfor mef(A)-positive isolates vs. >256 µg/mLfor
erm(B)-positive isolates and those harboring both the
erm(B) and mef(A) gene) (11).
Factors Contributing to Development 
and Spread of Macrolide Resistance
Inappropriate use of antimicrobial drugs is among the
most important factors associated with the emergence and
spread of pneumococcal macrolide resistance.
Inappropriate use may include using antimicrobial drugs to
treat nonmicrobial or self-limiting infections, using agents
with a spectrum of activity that either does not cover the
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spectrum of activity, and inappropriate dose or duration of
treatment (20).
Other risk factors for carriage or infection with resistant
pneumococcal strains include age (patients particularly at
risk include those <2 or >65 years of age), history of
macrolide use, and the presence of severe underlying dis-
ease (21). Analyses of data from national and international
surveillance studies have suggested a link between
increased use of macrolides and increased rates of pneu-
mococcal resistance (22). In Portugal, the emergence of
macrolide-resistant  S. pneumoniae strains from 1994 to
2002 correlated with the use of azithromycin during the
same period (23). Several studies have shown that
macrolide administration is associated with increased
nasopharyngeal carriage of resistant strains of S. pneumo-
niae in children (24); the clonal dissemination of
macrolide-resistant pneumococcal strains in crowded envi-
ronments (e.g., daycare centers, hospitals, jails, long-term
care facilities) is also thought to be a major factor con-
tributing to the spread of resistance.
Clinical Implications of Macrolide Resistance
Surveillance studies have shown that a substantial per-
centage of pneumococci are now macrolide resistant.
Despite this rising rate of in vitro resistance, some
researchers and clinicians have questioned whether resist-
ance to macrolides is clinically relevant given the high
concentrations achieved in respiratory tissues such as the
epithelial lining fluid. Although macrolide levels in epithe-
lial lining fluid have been reported to exceed the levels
achieved in serum, the relevance of the fluid levels has
been questioned (25), and sufficiently high macrolide
blood levels remain essential to cure bacteremic pneumo-
coccal pneumonia. Moreover, clinically achievable serum,
epithelial lining fluid, and middle-ear fluid concentrations
of azithromycin were insufficient to eradicate macrolide-
resistant  S. pneumoniae, irrespective of the resistance
mechanism (26). 
Prospective clinical studies have provided conflicting
evidence for an association between discordant antimicro-
bial therapy (i.e., use of an agent to which the causative
pathogen displayed in vitro resistance) and treatment out-
come. For example, while results from 1 study of patients
with community-acquired pneumonia and bacteremia due
to bacteremic pneumococcal infection demonstrated an
association between increased death rates and discordant
antimicrobial drug therapy (27), no such association was
observed in a different study (28) of patients with pneumo-
coccal community-acquired pneumonia. However, the
conclusions that can be drawn from such studies may be
limited by factors such as small sample size, differences in
patient inclusion or exclusion criteria (e.g., recent antimi-
crobial drug use), use of relatively insensitive measures of
treatment outcome (e.g., death), and use of single or mul-
tiple antimicrobial drugs (many hospitalized patients
receive combination antimicrobial therapy, thus limiting
the opportunities to study the effects of discordant treat-
ment on clinical outcomes); in the studies cited above,
none of the cases of discordant therapy involved
monotherapy with a macrolide. 
In acute otitis media, tympanocentesis performed
before and after drug therapy has been used in several
studies to determine the clinical relevance of antimicrobial
resistance. Using this method, Dagan et al. (29) showed
that microbiologic failure (correlated with clinical failure)
was associated with pneumococcal macrolide resistance
among patients treated with azithromycin; treatment of 6
of 6 patients with high-level macrolide resistance failed
microbiologically. Furthermore, analysis of data from a
pediatric medical center in the United States (30) noted
that the rising incidence of antimicrobial-resistant pneu-
mococci corresponded to an increase in suppurative com-
plications of acute otitis media and appeared to contribute
to more aggressive infections that required surgical inter-
vention. 
In recent years, several reports have described clinical
and microbiologic treatment failures that have occurred in
hospitalized patients infected with macrolide-resistant
pneumococci (31). Among these cases of treatment failure,
2 deaths occurred. In both cases, the previously healthy
patients (a 28 year-old man and a 49-year-old woman)
received monotherapy with intravenous azithromycin for
pneumonia. The clinical status of both patients deteriorat-
ed while they were receiving azithromycin, and macrolide-
resistant  S. pneumoniae were isolated from blood and
pleural fluid cultures taken while these patients were
receiving medication.
A matched case-control study of hospitalized patients
with bacteremia conducted by Lonks et al. (32) identified
86 patients with isolates of S. pneumoniae that were fully
or intermediately resistant to macrolides and 141 controls
who had macrolide-susceptible pneumococcal infection.
When patients with meningitis were excluded from the
analysis, 18 (24%) of 76 patients were taking a macrolide
at the time of bacteremia compared to none of the controls
(p<0.0001). Moreover, 5 (24%) of the 21 bacteremic
patients infected with pneumococci expressing the M phe-
notype were taking a macrolide (compared with none of
the 40 matched control patients; p<0.0016). These data
show that breakthrough bacteremia and treatment failure
occurred only in those patients infected with a macrolide-
resistant pneumococcus; no incidences of breakthrough
bacteremia were seen in those infected with a macrolide-
susceptible pneumococcus. Similarly, a study of all pneu-
mococcal bacteremias from a hospital in Belgium (33)
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ant pneumococcus were taking a macrolide when blood
cultures were obtained, i.e., they had breakthrough bac-
teremia; in contrast, none of the 103 patients with
macrolide-susceptible pneumococci was taking a
macrolide.
The overall incidence of treatment failure caused by
macrolide-resistant pneumococci cannot be estimated
from the case reports and observational studies published
to date. These reports of treatment failure likely only rep-
resent the tip of the iceberg, as most case studies published
to date have only captured treatment failures that resulted
in breakthrough bacteremia. These published studies
underreport the magnitude of treatment failures because
nonbacteremic pneumococcal pneumonia is 3–5 times
more common than bacteremic pneumonia. In addition,
these treatment failures resulted in hospitalization, which
is more expensive than outpatient therapy. Most
macrolides are prescribed as part of empiric treatment reg-
imens for ambulatory patients in the outpatient setting;
microbiologic cultures are not usually obtained from these
patients, and antimicrobial susceptibility testing is rarely
performed (even if treatment failure occurs).
Macrolide Resistance and Treatment Guidelines
In the United States, guidelines for the treatment of
community-acquired RTIs have been established by a
number of groups, including the American Thoracic
Society, the Infectious Diseases Society of America, the
Centers for Disease Control and Prevention (CDC), and
the Sinus and Allergy Health Partnership. The clinical rel-
evance of macrolide-resistant S. pneumoniae has been
addressed in updates to these groups’ guidelines for the
treatment of community-acquired pneumonia (34,35) and
in a report published by the Drug-Resistant Streptococcus
pneumoniae Therapeutic Working Group convened by
CDC (36). The consensus among these guidelines is that
empiric therapy should be stratified based on likely cause,
treatment setting (inpatient versus outpatient), and the risk
for pneumococcal antimicrobial resistance. In general, all
3 guidelines recommend that monotherapy with
macrolides should be restricted to specific patient sub-
groups (i.e., those with no coexisting cardiopulmonary dis-
ease and no risk factors for infection with drug-resistant S.
pneumoniae [e.g., recent antimicrobial drug use]). For out-
patients with risk factors for drug-resistant S. pneumoniae,
current recommended treatment options include combina-
tion therapy with a β-lactam (such as high-dose amoxi-
cillin or high-dose amoxicillin-clavulanate) plus a
macrolide or an antipneumococcal fluoroquinolone
(34,35). The increased use of fluoroquinolones has been
associated with the emergence and spread of resistance to
these agents (37), and local clonal dissemination of S.
pneumoniae strains with very high-level resistance to peni-
cillin has been reported in the United States (38). Although
the prevalence of these resistant isolates remains low, such
findings emphasize the necessity for local resistance pat-
terns to be considered when prescribing empiric antimicro-
bial drug therapy for patients with community-acquired
RTIs. 
The Sinus and Allergy Health Partnership guidelines
for the treatment of acute microbial rhinosinusitis also
highlight the need to consider the increasing prevalence of
pneumococcal resistance when making treatment choices,
with patients divided into categories dependent on their
recent exposure to antimicrobial drugs (39). Similarly, a
recent American Thoracic Society statement on the man-
agement of acute microbial exacerbations of chronic
obstructive pulmonary disease emphasizes the need to
consider local resistance patterns when prescribing antimi-
crobial drugs (40).
Conclusions
National and international surveillance studies demon-
strate a high global prevalence of in vitro macrolide resist-
ance among pneumococcal isolates obtained from patients
with community-acquired RTIs. In recent years, a number
of studies have clearly linked in vitro macrolide resistance
to microbiologic and clinical treatment failure, indicating
that macrolide resistance is an emerging problem. As
pneumococcal community-acquired RTIs (particularly
community-acquired pneumonia) are a leading cause of
illness and death worldwide, appropriate empiric antimi-
crobial therapy should be used to treat these infections.
Recent updates to a number of treatment guidelines have
reflected this changing situation by emphasizing the need
for clinicians to consider local antimicrobial resistance
patterns and risk factors for infection with drug-resistant
pathogens when prescribing empiric antimicrobial therapy. 
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